Daily Investment Strategy
Daily focus ： Real-Time Quote
MEDBOT-B (2252): Revenue is expected to double in 2025, with Toumai's overseas orders exceeding 100, demonstrating economies of scale. National pricing guidelines will be implemented in 2026, clearing obstacles to pricing and ensuring profits. Driven by "expanding external and domestic demand," combined with policy dividends and domestic substitution, the company is accelerating towards break-even. While regulatory competition needs to be monitored, it already possesses the key conditions to transition from high growth to large-scale profitability.
The IMF Raises Global Economic Growth Forecast to 3.3%
The International Monetary Fund (IMF) has raised its 2026 global growth forecast to 3.3%, affirming the resilience of the US and Chinese economies amid the AI investment boom. The IMF described the massive corporate investment in AI infrastructure as offsetting some of the negative impact of trade barriers. However, this positive development masks underlying structural concerns. The IMF specifically warned of the "imbalance" in the US-China growth models—namely, the US's high deficit consumption and China's export dependence—which could become a breeding ground for a resurgence of trade protectionism.
Hong Kong Stock Connect recorded a net inflow of HK$13.9 billion on Wednesday, with the Tracker Fund of Hong Kong (2800) recording the largest net inflow at HK$4.15 billion, followed by the Hang Seng China Enterprises Index (2828). China Mobile (941) recorded the largest net outflow at HK$920 million, followed by Tencent Holdings (700).
Leung Kai Tong is a SFC licensed person accredited to KGI Group to carry on regulated activities (for details, please refer to https://apps.sfc.hk/publicregWeb/indi/ADU276/details). He and/or his associate do not have any financial interest in the recommended issuer or new listing applicant.
The materials contained herein are provided by KGI Asia Limited ("KGI") for information only. While such materials are based on or derived from sources believed to be reliable, KGI makes no representation or warranty (express or implied) as to their accuracy or reliability. Neither the information nor the opinions expressed herein constitute, or are to be construed as, an offer or invitation or solicitation of an offer to buy or sell any securities or investments. KGI and its officers, employees, agents and affiliates may have interests in the securities or investments covered herein and accept no liability whatsoever for any loss or consequence whatsoever (whether direct or indirect) resulting from any use of or reliance by you on such materials.
